Novogen Limited Stock Price, News & Analysis (NASDAQ:NVGN)

$3.20 0.08 (2.56 %)
(As of 11/17/2017 02:34 PM ET)
Previous Close$3.12
Today's Range$3.08 - $3.20
52-Week Range$1.63 - $7.60
Volume8,400 shs
Average Volume8,582 shs
Market Capitalization$13.93 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.47

About Novogen Limited (NASDAQ:NVGN)

Novogen Limited logoNovogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:NVGN
  • CUSIP: N/A
  • Web: www.novogen.com
Debt:
  • Current Ratio: 3.62%
  • Quick Ratio: 3.62%
Sales & Book Value:
  • Annual Sales: $180,000.00
  • Price / Sales: 85.87
  • Book Value: $3.95 per share
  • Price / Book: 0.81
Misc:
  • Outstanding Shares: 4,830,000
 
Frequently Asked Questions for Novogen Limited (NASDAQ:NVGN)

What is Novogen Limited's stock symbol?

Novogen Limited trades on the NASDAQ under the ticker symbol "NVGN."

Where is Novogen Limited's stock going? Where will Novogen Limited's stock price be in 2017?

1 Wall Street analysts have issued twelve-month target prices for Novogen Limited's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Novogen Limited's stock price to reach $5.00 in the next twelve months. View Analyst Ratings for Novogen Limited.

Who are some of Novogen Limited's key competitors?

Who are Novogen Limited's key executives?

Novogen Limited's management team includes the folowing people:

  • James B. Garner, Chief Executive Officer, Executive Director (Age 43)
  • Gordon Hirsch, Chief Medical Officer
  • Lilischkis Kimberley, Clinical & Regulatory Affairs Manager
  • Peng K. Leong, Chief Business Officer
  • Stephen Palmer, Program Director - Degenerative Diseases
  • Justine R. Stehn Ph.D., Director - ATM Program
  • Kate Hill, Interim Company Secretary
  • Iain Ross, Non-Executive Chairman of the Board
  • Bryce Carmine, Non-Executive Deputy Chairman of the Board
  • Steven Roy Stent Coffey, Non-Executive Director

How do I buy Novogen Limited stock?

Shares of Novogen Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novogen Limited's stock price today?

One share of Novogen Limited stock can currently be purchased for approximately $3.20.

How big of a company is Novogen Limited?

Novogen Limited has a market capitalization of $13.93 million and generates $180,000.00 in revenue each year. The biotechnology company earns ($8,040,000.00) in net income (profit) each year or ($3.82) on an earnings per share basis.

How can I contact Novogen Limited?

Novogen Limited's mailing address is L 5 20 George St, SYDNEY, NSW 2077, Australia. The biotechnology company can be reached via phone at +61-2-94724101 or via email at [email protected]


MarketBeat Community Rating for Novogen Limited (NASDAQ NVGN)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Novogen Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Novogen Limited (NASDAQ:NVGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (56.25% upside)
Consensus Price Target History for Novogen Limited (NASDAQ:NVGN)
Price Target History for Novogen Limited (NASDAQ:NVGN)
Analysts' Ratings History for Novogen Limited (NASDAQ:NVGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/28/2017HC WainwrightSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Novogen Limited (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Novogen Limited (NASDAQ:NVGN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Novogen Limited (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novogen Limited (NASDAQ NVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Novogen Limited (NASDAQ:NVGN)
Latest Headlines for Novogen Limited (NASDAQ NVGN)
Source:
DateHeadline
Edison Issues ADR Update on Novogen (NVGN)Edison Issues ADR Update on Novogen (NVGN)
finance.yahoo.com - September 12 at 7:17 AM
Head-To-Head Analysis: Novogen Limited (NVGN) versus Compugen (CGEN)Head-To-Head Analysis: Novogen Limited (NVGN) versus Compugen (CGEN)
www.americanbankingnews.com - September 5 at 2:22 AM
Australian cancer specialists may hold key to next advancement in ovarian cancer treatmentAustralian cancer specialists may hold key to next advancement in ovarian cancer treatment
finance.yahoo.com - August 31 at 8:00 AM
Board Review of Business Operations and GovernanceBoard Review of Business Operations and Governance
finance.yahoo.com - August 14 at 12:44 AM
Progress Update on Cantrixil(TM) (TRXE-002-1) DevelopmentProgress Update on Cantrixil(TM) (TRXE-002-1) Development
finance.yahoo.com - August 7 at 12:38 AM
Brainstorm Cell Therapeutics (BCLI) and Novogen Limited (NVGN) Head to Head SurveyBrainstorm Cell Therapeutics (BCLI) and Novogen Limited (NVGN) Head to Head Survey
www.americanbankingnews.com - August 2 at 6:23 PM
Novogen announces changes in the Board of Directors and a cost reduction programNovogen announces changes in the Board of Directors and a cost reduction program
seekingalpha.com - June 9 at 12:50 AM
Novogen bags development of AnisinaNovogen bags development of Anisina
seekingalpha.com - April 7 at 11:36 AM
Novogen nabs $3M grant to fund new cancer therapies; shares up 5%Novogen nabs $3M grant to fund new cancer therapies; shares up 5%
seekingalpha.com - February 10 at 1:03 AM
5:43 pm Novogen awarded grant of up to AUD $3 mln by the Australian federal government to fund development of a next-generation anti-tropomyosin program5:43 pm Novogen awarded grant of up to AUD $3 mln by the Australian federal government to fund development of a next-generation anti-tropomyosin program
us.rd.yahoo.com - February 8 at 7:50 PM
Novogen (NVGN) Acquires Australian Biotech Company Glioblast PtyNovogen (NVGN) Acquires Australian Biotech Company Glioblast Pty
www.streetinsider.com - November 2 at 6:51 PM
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in GlioblastomaNovogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma
www.prnewswire.com - October 31 at 1:07 PM
Novogen Limited (NVGN) Down on Glioblast PurchaseNovogen Limited (NVGN) Down on Glioblast Purchase
www.baystreet.ca - October 31 at 1:07 PM
Novogen ups commitment to brain cancer with acquisition of Glioblast and license of product candidate GDC-0084 from GenentechNovogen ups commitment to brain cancer with acquisition of Glioblast and license of product candidate GDC-0084 from Genentech
seekingalpha.com - October 31 at 1:07 PM
Novogen (NVGN) Hikes on FDA NodNovogen (NVGN) Hikes on FDA Nod
www.baystreet.ca - September 12 at 11:06 AM
Novogen secures key US drug study approvalNovogen secures key US drug study approval
au.finance.yahoo.com - September 12 at 11:05 AM
Novogen Submits IND Application For Cantrixil In Ovarian Cancer To FDANovogen Submits IND Application For Cantrixil In Ovarian Cancer To FDA
www.nasdaq.com - August 12 at 9:46 AM
Novogen Provides Update On Development Of Cantrixil - PR Newswire (press release)Novogen Provides Update On Development Of Cantrixil - PR Newswire (press release)
www.prnewswire.com - May 3 at 2:24 PM
Anavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking AlphaAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking Alpha
seekingalpha.com - April 27 at 2:54 PM
Novogen appoints new CEONovogen appoints new CEO
au.finance.yahoo.com - December 9 at 7:56 PM

Social Media

Financials

Chart

Novogen Limited (NASDAQ NVGN) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.